Navigation Links
The LCA-Vision Full Value Committee Files Detailed Presentations
Date:2/25/2009

Outlines the Sharp and Substantial Deterioration of Stockholder Value under the Current Board and Management Team

Discloses Details of Plan to Restore Value for Benefit of All Stockholders

CINCINNATI, Feb. 25 /PRNewswire/ -- The LCA-Vision Full Value Committee announced today that it has filed presentations with the Securities and Exchange Commission in connection with the Full Value Committee's solicitation of consents to replace the existing Board of Directors of LCA-Vision, Inc. (Nasdaq: LCAV) ("LCAV") with the Full Value Committee's five highly qualified nominees. The presentations provide (i) a comprehensive review of the multiple problems currently facing LCAV as a result of the grave failures by the LCAV Board and senior management to prudently manage the critical drivers of the business, (ii) specific details about the Full Value Committee's plan for restoring value at LCA-Vision, and (iii) a thorough analysis of the reasons we believe the current management's plan is destined to fail. The presentations and other proxy materials are available free of charge at www.sec.gov or at www.LCAVisionFullValueCommittee.com.

In the presentations, the Full Value Committee outlines LCA-Vision's dramatic financial underperformance and shows that significant operational, financial and governance problems continue to plague the Company and materially impair stockholder value. Specifically, the presentations address and detail:

  • The Financial Catastrophe that has taken place under CEO Steve Straus and the current Board, including the sharp deterioration in LCA-Vision's stock price; market capitalization; enterprise value; cash flows; same store procedural volume and revenues; marketing efficiencies and effectiveness; and market share, among other key metrics;
  • The Numerous Failures of the Current LCA-Vision Board and Senior Management Team; and
  • The Full Value Committee's Turnaround Plan for Restoring Value at LCA-Vision, including how they will grow the current business; restore the broken relationships with the Company's affiliated physicians, who generate 100% of the Company's revenues; work to improve efficiency and reduce costs strategically; build marketing into a core competency of the Company and significantly drive down marketing costs; and how they will improve patient quality of care, among other key initiatives.

The Full Value Committee urges all stockholders to vote the WHITE consent card to help remove the current Board that has presided over a loss of over $1 billion in stockholder value and, in its place, to install competent, experienced directors and a proven executive management team with the financial incentives, commitment and requisite experience to Restore the Value and Restore the Vision to LCA-Vision. Vote for change on the WHITE consent card -- Today!

CERTAIN INFORMATION CONCERNING PARTICIPANTS

On February 6, 2009, The LCA-Vision Full Value Committee made a definitive filing with the Securities and Exchange Commission ("SEC") of a consent solicitation statement relating to the solicitation of written consents from stockholders of the Company in connection with seeking to remove and replace the current members of the Board of Directors of the Company.

THE LCA-VISION FULL VALUE COMMITTEE ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE CONSENT SOLICITATION STATEMENT AND ANY OTHER SOLICITATION MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION. SUCH SOLICITATION MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS SOLICITATION WILL PROVIDE COPIES OF THE CONSENT SOLICITATION STATEMENT WITHOUT CHARGE UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' SOLICITOR BY CALLING, TOLL-FREE, (888) 750-5834.

The participants in the consent solicitation are Dr. Stephen N. Joffe, Craig P.R. Joffe, Alan H. Buckey, Jason T. Mogel, Robert Probst, Robert H. Weisman and Edward J. VonderBrink.

As of the date of this filing, Dr. Joffe directly beneficially owns 1,171,952 shares of Common Stock of the Company, Craig P.R. Joffe directly beneficially owns 865,468 shares of Common Stock of the Company, and Alan H. Buckey directly beneficially owns 77,900 shares of Common Stock of the Company.

For the purposes of Rule 13d-5(b)(1) of the Securities Exchange Act of 1934, as amended, each of the participants in this solicitation is deemed to beneficially own the shares of Common Stock of the Company beneficially owned in the aggregate by the other participants. Each of the participants in this proxy solicitation disclaims beneficial ownership of such shares of Common Stock except to the extent of his or its pecuniary interest therein.


'/>"/>
SOURCE The LCA-Vision Full Value Committee
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. LCA-Vision Reports Tangible Results from Business Strategy
2. LCA-Vision Announces Appointment of Edgar F. Heizer to Board of Directors
3. LCA-Vision Announces Consent Solicitation Deadline; Urges Stockholders to Return Gold Consent Revocation Card
4. LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results
5. LCA-Visions National Lasik Network Named as U.S. Provider for National Vision Administrators
6. The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders
7. LCA-Vision to Hold Corporate Update Conference Call and Q&A Session on February 6
8. LCA-Vision to Announce Fourth Quarter and Full Year 2008 Financial Results on Tuesday, February 10, 2009
9. The LCA-Vision Full Value Committee Files Preliminary Consent Solicitation Statement to Reconstitute the Board of Directors of LCA-Vision Inc.
10. LCA-Vision Urges Stockholders to Take No Action Regarding the Joffe Groups Threatened Consent Solicitation
11. LCA-Visions Former Executive Management Team Sends Open Letter to LCA-Vision Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 2017 , ... The Ellis Agency, an eastern Georgie provider of insurance management ... wide charity event with the goal of bringing in support for epilepsy patients in ... with epilepsy, recently launched a charity campaign of her own by donating her birthday ...
(Date:7/21/2017)... ... , ... Fresh Wave® IAQ today announced the launch of its innovative ... at the APPA 2017 Annual Conference and Exhibition in Booth #414. , ... the use of harsh chemicals, Fresh Wave IAQ Smoke Away Air & Fabric Liquid ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm ... the contents of its ginger ale for allegedly containing no ginger. Dr. Pepper produces ... Snapple Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how ... their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. ... on Kickstarter on Monday, July 21st. , The kit uses colorful, engaging and ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... cruciate ligament (ACL) offer patients improved quality of life five years after injury, ... Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed patients for ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... July 20, 2017  Prime Therapeutics LLC (Prime) released this ... M.D., following today,s Institute for Clinical and Economic Review,s (ICER) ... the effectiveness and value of abuse-deterrent formulations (ADF) of opioids. ... roundtable at the meeting. ... cost benefit to the use of abuse-deterrent formulations (ADF) in ...
(Date:7/14/2017)... LAS VEGAS , July 13, 2017 It ... the United States is in the midst of ... Disease Control , since 1999, the number of overdose deaths ... , "resulting in over half a million dead from 2001 ... like codeine, oxycodone, and hydrocodone has similarly quadrupled, drawing a ...
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
Breaking Medicine Technology: